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regulates liver hepcidin expression, acting, therefore, as
a hepcidin-inhibitory hormone  [1, 5] . Anaemia/hypoxia 
seems to be the third factor that regulates hepcidin ex-
pression. In fact, anaemia is associated with a decrease in 
hepcidin expression, resulting in an increase in intestinal 
iron absorption and iron release by the macrophages in 
order to augment iron availability for erythropoiesis  [6] .
 We sought, therefore, to study the relationship be-
tween hepcidin serum levels and haematological data, 
iron status, inflammatory markers and rhEPO doses in 
HD patients.
 We selected 33 HD patients (15 males, 18 females; 
mean age 59.5  8 17.6 years) under rhEPO treatment for 
a median time period of 36 months. All patients used the 
high-flux polysulfone FX-class dialyzers of Fresenius. 
The HD patients included 16 responders and 17 non-re-
sponders to rhEPO therapy. Classification of HD pa-
tients, as responders or non-responders, was performed 
in accordance with the European Best Practice Guide-
lines  [5] . The rhEPO maintenance dose for responder pa-
 Recently, a complex regulatory network that governs 
iron traffic has emerged, and points to hepcidin as a ma-
jor evolutionary conserved regulator of iron distribution 
 [1, 2] . This small hormone produced by the mammalian 
liver has been proposed as a central mediator of dietary 
iron absorption. Hepcidin was found to be associated 
with decreases in both iron uptake from the small intes-
tine and release of iron from macrophages, as well as de-
creased placental iron transport  [1, 2] . The synthesis of 
hepcidin is stimulated by anaemia/hypoxia, inflamma-
tion and iron overload. It is synthesized as a preprohep-
cidin of 84 amino acids. The signal peptide is cleaved 
leading to the 60-amino acid prohepcidin, which is fur-
ther processed giving rise to the 25-amino acid hepcidin 
 [3, 4] . 
 Hepcidin synthesis is regulated by inflammation, a 
common finding in haemodialysis (HD) patients, being 
enhanced in those that do not respond to recombinant 
human erythropoietin (rhEPO) therapy. On the other 
hand, it will be demonstrated that erythropoietin down-
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tients was 95.9  8 68.5 U/kg/week and for non-respond-
ers it was 512.6  8 215.0 U/kg/week. The 2 groups of pa-
tients were matched for age, gender, weight, body mass 
index, mean time on HD, urea reduction ratio, urea KtV 
and parathyroid hormone serum levels. Patients with au-
toimmune disease, malignancy, haematological disor-
ders, acute or chronic infection and blood transfusion 
within the last 4 months were excluded from the study. 
Healthy volunteers (n = 17) with normal haematological 
and biochemical values and without any history of renal 
or inflammatory disease were used as normal controls. 
They were matched as far as possible for age and gender 
with HD patients. 
 In all patients and controls, red blood cell (RBC) count, 
haematocrit, haemoglobin (Hb) concentration, haemato-
logical indices and red cell distribution width (RDW) 
were measured by using an automatic blood cell counter 
(Sysmex K1000; Sysmex, Hamburg, Germany). Serum 
iron concentration was determined using a colorimetric 
method (iron; Randox Laboratories Ltd., Crumlin, UK), 
whereas serum ferritin and serum transferrin (Randox 
Laboratories) were measured by immunoturbidimetry. 
Enzyme-linked immunosorbent assays were used for 
measurement of plasma soluble transferrin receptor (s-
TfR; human sTfR immunoassay, R&D Systems, Minne-
apolis, Minn., USA) and serum prohepcidin concentra-
tions (Hepcidin Prohormone ELISA; IBL, Hamburg, 
Germany). Serum C-reactive protein (CRP) was deter-
mined by nephelometry (N high sensitivity CRP; Dade 
Behring, Germany), and serum IL-6 levels were quanti-
fied using the BD TM Cytometric Bead Array Human Th1/
Th2 Cytokine Kit II (BD Biosciences, San Diego, Calif., 
USA), and analyzed using the BD TM CBA Software. 
 Serum hepcidin measurements were performed by a 
combination of weak cation exchange chromatography 
and time-of-flight mass spectrometry. An internal stan-
dard (synthetic hepcidin-24; Peptide International Inc., 
Louisville, Ky., USA) was used for quantification. Peptide 
spectra were generated on a Microflex LT matrix-en-
hanced laser desorption/ionization time-of-flight mass 
spectrometry platform (Bruker Daltonics, Germany). 
 Serum hepcidin-25 concentrations were expressed as 
nmol/l. The lower limit of detection of this method was 
0.5 nmol/l; average coefficients of variation were 2.7% 
(intrarun) and 6.5% (interrun)  [7, 8] . 
 For statistical analysis, we used the Statistical Package 
for Social Sciences, version 14.0. Kolmogorov-Smirnov 
statistics were used to evaluate sample normality distri-
bution. Comparisons between groups were performed 
using Kruskal-Wallis test and Mann-Whitney U (data 
with a non-Gaussian distribution) or one-way ANOVA 
supplemented with Tukey’s HSD post hoc test (data with 
a Gaussian distribution). Spearman’s rank correlation co-
efficient was used to evaluate relationships between sets 
of data. Multiple regression analysis using the stepwise 
method was used to determine independent factors (Hb 
concentration, RBC count, haematocrit, serum levels of 
transferrin, ferritin, s-TfR, CRP and interleukin 6, and 
weekly rhEPO dose) affecting prohepcidin and hepcidin 
serum levels. Significance was accepted at p  ! 0.05.
 Compared to controls, HD patients presented with 
significantly lower RBC count (3.6  8 0.6 vs. 4.7  8 0.5  ! 
10 12 /l, p  ! 0.05), Hb concentration (11.0  8 1.7 vs. 13.8  8 
1.1 g/dl, p  ! 0.05), haematocrit (34.0  8 5.0 vs. 42.6  8 
3.8%, p  ! 0.05) and transferrin levels (181.8  8 57.5 vs. 
247.6  8 58.4 mg/dl, p  ! 0.05), and significantly higher 
RDW (16.0  8 3.1 vs. 12.7  8 0.6%, p  ! 0.05), serum fer-
ritin [334.0 ng/ml (174.0–462.9) vs. 87.0 ng/ml (21.9–
113.1), p  ! 0.05], s-TfR (27.1  8 7.6 vs. 22.7  8 9.8 nmol/l, 
p  ! 0.05), CRP [5.7 mg/dl (2.4–16.5) vs. 1.5 mg/dl (0.8–
4.9), p  ! 0.05], IL-6 [8.1 pg/ml (4.8–13.7) vs. 1.9 pg/ml 
(0–3.8), p  ! 0.05], prohepcidin [113.4 ng/ml (82.5–168.2) 
vs. 89.5 ng/ml (78.4–102.1), p  ! 0.05] and hepcidin levels 
[8.8 nmol/l (3.8–14.1) vs. 2.3 nmol/l (0–3.25), p  ! 0.05]. 
No statistically significant differences were found on 
transferrin saturation between controls and HD patients. 
Among HD patients, non-responders had lower Hb (10.5 
 8 1.9 vs. 11.6  8 1.3 g/dl, p  ! 0.05), haematocrit (32.7  8 
5.7 vs. 35.4  8 3.9%, p  ! 0.05), and higher RDW (17.5  8 
3.7 vs. 14.5  8 1.0%, p  ! 0.05), s-TfR (33.5  8 22.4 vs. 23.8 
 8 8.4 nmol/l) and CRP levels [5.9 mg/dl (2.8–32.9) vs. 3.2 
mg/dl (1.7–13.5), p  ! 0.05]. No statistically significant
differences regarding transferrin saturation were found 
between responder and non-responder patients. Prohep-
cidin serum levels among non-responders were signifi-
cantly lower than among responders [122.5 ng/ml (87.9–
161.0) vs. 141.2 ng/ml (75.2–186.7)], but were higher than 
those in the control group. The same trend was found for 
hepcidin serum levels ( fig. 1 ).
 A statistically significant correlation was found be-
tween hepcidin serum levels and some haematological 
data [RBC count (r = –0.318, p = 0.025), mean cell volume 
(r = 0.484, p  ! 0.001), mean cell Hb (r = 0.467, p = 0.001) 
and RDW (r = 0.366, p = 0.01)], iron status markers [fer-
ritin (r = 0.754, p  ! 0.0001) and transferrin (r = –0.508,
p  ! 0.0001)] and inflammatory markers [CRP (r = 0.359, 
p = 0.027) and interleukin 6 (r = 0.547, p = 0.001)]. We also 
found a positive correlation between prohepcidin and 
hepcidin serum levels (r = 0.624, p  ! 0.0001). Multiple 
regression analysis showed that CRP as an independent 
variable was significantly associated with hepcidin se-
rum levels (  = 0.62; p = 0.06).
 We found that HD patients had higher serum levels of 
prohepcidin and hepcidin as well as higher levels of mark-
ers of chronic inflammation such as ferritin, CRP and 
IL-6, and markers of reduced iron mobilization such as 
lower levels of transferrin. These results suggest that the 
high levels of hepcidin found in HD patients could be re-
lated to an underlying chronic inflammation. Moreover, 
correlations between hepcidin and inflammatory mark-
ers (CRP and IL-6) and multiple regression analysis cor-
roborate this finding. 
 Among HD patients, we found that the non-respond-
ers to rhEPO therapy presented with more severe anae-
mia, as shown by the significantly lower levels of Hb com-
pared to responders. However, no statistically significant 
differences were found in serum iron status markers be-
tween the groups of patients, except for the s-TfR, which 
was higher among non-responders. The levels of this sol-
uble receptor could be increased in two clinical settings: 
increased erythropoietic activity or iron deficiency  [9] . 
As previously described  [5] , in our patients, s-TfR was an 
indicator of the erythropoietic effect of administrated 
rhEPO and not an indicator of iron body status. More-
over, no differences were found between responder and 
non-responder HD patients concerning iron status mark-
ers, which excludes a decrease in iron availability as the 
principal cause of the elevated s-TfR found in non-re-
sponder HD patients. As previously described  [5] , CRP is 
higher in HD patients who are non-responders to rhEPO 
therapy, indicating that inflammation is related to resis-
tance to this therapy, which suggests that CRP is a good 
predictor of resistance to rhEPO therapy in HD pa-
tients. 
 Excessive hepcidin production occurs in patients with 
inflammatory and infectious diseases, resulting in anae-
mia of inflammation. As non-responder patients present 
high inflammatory markers, prohepcidin and hepcidin 
serum levels might be expected to be increased in non-
responder patients. However, we found that non-respond-
er patients present lower prohepcidin and a trend for low-
er hepcidin serum levels. Recently it has been demon-
strated that erythropoietin downregulates liver hepcidin 
expression, acting, therefore, as a hepcidin inhibitory 
hormone  [1] . Since non-responders were treated with 
much higher doses of rhEPO compared with responders, 
the lower prohepcidin and hepcidin levels among non-
responders could be explained by this mechanism. On a 
broader note, despite the treatment with rhEPO, HD pa-
tients showed higher levels of prohepcidin and hepcidin. 
This could be explained by the fact that the stimulus of 
inflammation for prohepcidin synthesis in HD patients 
is stronger than the inhibitory effect of rhEPO. In addi-
tion, the use of large amounts of rhEPO may lead to in-
creased iron utilization by the bone marrow, resulting in 
depletion of iron stores and ultimately decreased intra-
cellular iron availability, which could also decrease pro-
hepcidin and hepcidin levels. Additional explanations for 
the lower prohepcidin and hepcidin levels in rhEPO non-
responder patients could be lower intracellular iron avail-
ability (as reflected by the increased s-TfR observed in the 
non-responder group) and anaemia found in HD pa-
tients, as reflected by the negative correlation between 
RBC count and hepcidin serum levels. 
 In conclusion, our data show that the high hepcidin 
serum levels, found in HD patients, are dependent on the 
magnitude of the inflammatory process and on rhEPO 
doses. A close interaction between haematological data, 
inflammation, iron status and hepcidin serum levels, 
which ultimately regulate intracellular iron availability, 
was also found in our HD patients. Hepcidin seems to 
play a significant role in anaemia of HD patients; how-
ever, it is difficult to use it as a clinical marker due to the 
many influences and interrelations.
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 Fig. 1. Serum hepcidin levels among controls and HD patients ac-
cording to the response to rhEPO therapy. Box plot shows median 
value (horizontal line in box) and first and third quartiles (lines 
above and below the box, respectively). 
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